ClinicalTrials.gg
CompletedNCT06581627Updated Dec 29, 2025

A Research Study Looking at a Single Dose of Etavopivat in Healthy Chinese Participants

A Phase 1 interventional study of Etavopivat in Healthy Volunteers, Sickle Cell Disease and Thalassemia, sponsored by Novo Nordisk A/S. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-29.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Anemia, Sickle Cell by Novo Nordisk A/S — 4 open to participants now, 5 under way, 3 of them phase 3. Anemia, Sickle Cell · Novo Nordisk A/S.

Enrollment
10th of 11
24 · median 95
Started
2024
with 1 other
Phase 1
3 of 11
none open now
Registered
8th of 11
by date

Among the 11 studies in Anemia, Sickle Cell by Novo Nordisk A/S, this one is the 10th largest by enrollment, is one of 2 that started in 2024, is one of 3 in phase 1, and was the 8th registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

4 of the 11 studies in Anemia, Sickle Cell by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Anemia, Sickle Cell by Novo Nordisk A/S, or all of them as a file.
02

Study summary

The study tests a new medicine called etavopivat in healthy Chinese participants. During the study, the participant will be given 1 dose of the study medicine. A dose is 2 tablets which are swallowed together with a cup of water. The study doctor will measure how much of the study medicine is in the blood as time passes. After the dose is given, the study will last for 7 to 9 days. The participants will attend a screening visit 2 to 28 days before they are given the study medicine. The participant will have 6 clinic visits in total. As part of the study, participant will stay overnight at the clinic for 3 nights. In some cases the doctor may decide that participant need to stay more nights. Participant will have blood tests and other health assessments at all 6 visits. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period. If the participant do take part in the study, participant will need to refrain from certain activities and behaviours for up to 3 months before taking the study medicine. Participant will also need to go without food and drinks other than water in the 10 hours before and 4 hours after taking the medicine.

03

Conditions studied

  • Healthy Volunteers
  • Sickle Cell Disease
  • Thalassemia
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female Chinese participants.
  • Age 18-45 years (both inclusive) at the time of signing the form.
  • (BMI) between 18.0 and 33.0 kg/m\^2 (both inclusive) at screening.
  • Body weight greater than or equal to 40.0 kg at screening.
  • Considered to be generally healthy based on the medical history, physical examination and the results of vital signs, (ECG) and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using adequate methods.
  • Participation (i.e., signed ) in any other interventional clinical study within 90 days or 5 times the half-life of the previous medical product (IMP) (if known), whichever is longer before screening.
  • Any disorder, unwillingness or inability, which in the investigator's opinion might jeopardise the participant's safety or compliance with the protocol.
  • Use of any medication with unknown or unspecified content within 90 days before screening.
  • Use of prescription medicinal products or non-prescription drugs (including Chinese traditional medicine or local medicine) within 14 days before screening, as declared by the participant, apart from:
  • Acceptable contraceptive methods
  • Hormone replacement therapy (for menopausal females)
  • Over-the-counter topical medications known to not reach systemic circulation
  • Occasional use of:
  • Acetaminophen up to 2 grams (g) (4 x 0.5 g) daily
  • Ibuprofen up to 2.4 g (4 x 0.6 g) daily
  • Acetylsalicylic acid up to 2.4 g (4 x 0.6 g) daily
  • Is unable to refrain from or anticipates the use of any drug known to be a strong or moderate inhibitor or inducer of uridine 5'-diphospho glucuronosyltransferase (UGT) enzymes, cytochrome P450 (CYP) 3A4, CYP2C9 or permeability glycoproteins (P-gp), including St. John's Wort, for 28 days prior to dosing and throughout the study
  • Is unable to refrain from or anticipates the use of any medications or substances prohibited in the study
  • Use of tobacco and nicotine products, defined as any of the following:
  • Has used any product containing tobacco or nicotine within 90 days prior to screening
  • Not willing to refrain from the use of any product containing tobacco or nicotine throughout the study
  • Positive nicotine test at screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Etavopivat

    Participants will be administered a single dose of 2 tablets of etavopivat together.

    Drug: Etavopivat

Interventions

  • 2 tablets of Etavopivat will be administered in fasted state via oral route

06

What researchers measure

Primary outcomes

  1. AUC0-inf,etavopivat: Area under the etavopivat plasma concentration-time curve from 0 hours and extrapolated to infinity after a single dose

    Measured in hour\*nanogram/millilitre (h\*ng/mL).

    Time frame: From 0 to 120 hours after investigational medicinal product (IMP) administration (day 6)

  2. Cmax,etavopivat: Maximum observed etavopivat plasma concentration after a single dose

    Measured in nanograms/millilitre (ng/mL).

    Time frame: From 0 to 120 hours after investigational medicinal product (IMP) administration (day 6)

  3. Weight-adjusted AUC0-inf,etavopivat: Area under the etavopivat plasma concentration-time curve from 0 hours and extrapolated to infinity after a single dose divided by body weight

    Measured in(hour\*nanogram/millilitre)/kilograms ((h\*ng/mL)/kg).

    Time frame: From 0 to 120 hours after investigational medicinal product (IMP) administration (day 6)

  4. Weight-adjusted Cmax,etavopivat: Maximum observed etavopivat plasma concentration after a single dose divided by body weight

    Measured in (nanograms/millilitre )/kilogram ((ng/mL)/kg).

    Time frame: From 0 to 120 hours after investigational medicinal product (IMP) administration (day 6)

  5. AUC0-last,etavopivat: Area under the etavopivat plasma concentration-time curve from0 hours to the time of last quantifiable concentration

    Measured in hour\*nanogram/millilitre (h\*ng/mL).

    Time frame: From 0 to 120 hours after investigational medicinal product (IMP) administration (day 6)

  6. tmax,etavopivat: Time to maximum observed etavopivat plasma concentration after a single dose

    Measured in hour (h).

    Time frame: From 0 to 120 hours after investigational medicinal product (IMP) administration (day 6)

  7. t½,etavopivat: Terminal half-life for etavopivat after a single dose

    Measured in hour (h).

    Time frame: From 0 to 120 hours after investigational medicinal product (IMP) administration (day 6)

  8. CL/F etavopivat: Apparent plasma clearance of etavopivat after a single dose

    Measured in Litre/hour (L/h).

    Time frame: From 0 to 120 hours after investigational medicinal product (IMP) administration (day 6)

  9. Vz/F etavopivat: Apparent volume of distribution of etavopivat after a single dose based on plasma concentration values

    Measure in litre (L).

    Time frame: From 0 to 120 hours after investigational medicinal product (IMP) administration (day 6)

Secondary outcomes

  1. Number of adverse events

    Measured as count.

    Time frame: From dosing (day 1) to end of study (day 7 to 9)

07

Study locations

1 site
  • Beijing Hospital
    Beijing, Beijing Municipality 100730, China
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Oct 2024, 2 months.

Of 28 industry-sponsored phase 1 interventional studies under Anemia, Sickle Cell, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's 2 months is below that.

Counting every sponsor, half of 58 studies reached it within 36 months; a quarter within 18 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2024
First posted
Sep 3, 2024
StartActual
Aug 26, 2024
Primary completionActual
Oct 31, 2024
CompletionActual
Oct 31, 2024
Last update
Dec 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06581627
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Sep 3, 2024
Start date
Aug 26, 2024
Primary completion
Oct 31, 2024
Completion
Oct 31, 2024
Last update
Dec 29, 2025

Study contacts

Clinical Transparency '(dept. 2834)'
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etavopivat

Start the discussion